Gestational Diabetes Mellitus

Emily D. Szmuilowicz; Jami L. Josefson; Boyd E. Metzger

doi:10.1016/j.ecl.2019.05.001

Gestational Diabetes Mellitus

Emily D. Szmuilowicz, Jami L. Josefson, Boyd E. Metzger^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

189 Scopus citations

Abstract

Although it has been accepted for decades that women with gestational diabetes mellitus (GDM) are at high risk for future development of type 2 diabetes, vigorous debate regarding the value of detecting and treating GDM has persisted into the twenty-first century. Although results from 2 randomized trials provide strong evidence that treating GDM reduces adverse perinatal outcomes, it remains to be determined whether treatment impacts long-term offspring outcomes. Insulin is the first-line pharmacologic treatment and is added when glycemic goals are not met with nutritional modifications. Oral agent use is controversial, as data on long-term offspring outcomes are lacking.

Original language	English (US)
Pages (from-to)	479-493
Number of pages	15
Journal	Endocrinology and Metabolism Clinics of North America
Volume	48
Issue number	3
DOIs	https://doi.org/10.1016/j.ecl.2019.05.001
State	Published - Sep 2019

Funding

Keywords

Diagnosis
Gestational diabetes mellitus
Offspring
Outcomes
Pregnancy
Treatment

ASJC Scopus subject areas

Endocrinology
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ecl.2019.05.001

Cite this

@article{2dac983f232b4cdcb203bc458a34921b,

title = "Gestational Diabetes Mellitus",

abstract = "Although it has been accepted for decades that women with gestational diabetes mellitus (GDM) are at high risk for future development of type 2 diabetes, vigorous debate regarding the value of detecting and treating GDM has persisted into the twenty-first century. Although results from 2 randomized trials provide strong evidence that treating GDM reduces adverse perinatal outcomes, it remains to be determined whether treatment impacts long-term offspring outcomes. Insulin is the first-line pharmacologic treatment and is added when glycemic goals are not met with nutritional modifications. Oral agent use is controversial, as data on long-term offspring outcomes are lacking.",

keywords = "Diagnosis, Gestational diabetes mellitus, Offspring, Outcomes, Pregnancy, Treatment",

author = "Szmuilowicz, {Emily D.} and Josefson, {Jami L.} and Metzger, {Boyd E.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = sep,

doi = "10.1016/j.ecl.2019.05.001",

language = "English (US)",

volume = "48",

pages = "479--493",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Gestational Diabetes Mellitus

AU - Szmuilowicz, Emily D.

AU - Josefson, Jami L.

AU - Metzger, Boyd E.

PY - 2019/9

Y1 - 2019/9

N2 - Although it has been accepted for decades that women with gestational diabetes mellitus (GDM) are at high risk for future development of type 2 diabetes, vigorous debate regarding the value of detecting and treating GDM has persisted into the twenty-first century. Although results from 2 randomized trials provide strong evidence that treating GDM reduces adverse perinatal outcomes, it remains to be determined whether treatment impacts long-term offspring outcomes. Insulin is the first-line pharmacologic treatment and is added when glycemic goals are not met with nutritional modifications. Oral agent use is controversial, as data on long-term offspring outcomes are lacking.

AB - Although it has been accepted for decades that women with gestational diabetes mellitus (GDM) are at high risk for future development of type 2 diabetes, vigorous debate regarding the value of detecting and treating GDM has persisted into the twenty-first century. Although results from 2 randomized trials provide strong evidence that treating GDM reduces adverse perinatal outcomes, it remains to be determined whether treatment impacts long-term offspring outcomes. Insulin is the first-line pharmacologic treatment and is added when glycemic goals are not met with nutritional modifications. Oral agent use is controversial, as data on long-term offspring outcomes are lacking.

KW - Diagnosis

KW - Gestational diabetes mellitus

KW - Offspring

KW - Outcomes

KW - Pregnancy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85067296715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067296715&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2019.05.001

DO - 10.1016/j.ecl.2019.05.001

M3 - Review article

C2 - 31345518

AN - SCOPUS:85067296715

SN - 0889-8529

VL - 48

SP - 479

EP - 493

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

IS - 3

ER -

Gestational Diabetes Mellitus

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this